 The purpose of this study is to provide dose-finding information regarding the efficacy and kinetics of peripheral blood progenitor cell PBPC mobilisation by pegfilgrastim and to determine if carboplatinpaclitaxel can be delivered at a reduced cycle interval when supported by pegfilgrastim-mobilised PBPCs in whole blood. 